Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $5.3 million.

  • Puma Biotechnology's Change in Accured Expenses fell 5472.25% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year decrease of 24545.36%. This contributed to the annual value of -$15.8 million for FY2024, which is 10866.41% down from last year.
  • Per Puma Biotechnology's latest filing, its Change in Accured Expenses stood at $5.3 million for Q3 2025, which was down 5472.25% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Accured Expenses ranged from a high of $22.2 million in Q3 2021 and a low of -$30.9 million during Q1 2022
  • In the last 5 years, Puma Biotechnology's Change in Accured Expenses had a median value of -$1.6 million in 2023 and averaged -$2.7 million.
  • As far as peak fluctuations go, Puma Biotechnology's Change in Accured Expenses tumbled by 418207.89% in 2021, and later surged by 128348.93% in 2022.
  • Puma Biotechnology's Change in Accured Expenses (Quarter) stood at $1.5 million in 2021, then skyrocketed by 1283.49% to $20.7 million in 2022, then tumbled by 45.26% to $11.3 million in 2023, then plummeted by 221.48% to -$13.8 million in 2024, then skyrocketed by 138.35% to $5.3 million in 2025.
  • Its Change in Accured Expenses was $5.3 million in Q3 2025, compared to $4.9 million in Q2 2025 and -$9.9 million in Q1 2025.